Sysmex Corporation ADR (OTCMKTS:SSMXY) Sees Large Drop in Short Interest

Sysmex Corporation ADR (OTCMKTS:SSMXY) saw a significant decrease in short interest in the month of January. As of January 15th, there was short interest totaling 127,705 shares, a decrease of 53.9% from the December 31st total of 277,294 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average daily trading volume, of 698,584 shares, the days-to-cover ratio is presently 0.2 days. Based on an average daily trading volume, of 698,584 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.0% of the company’s stock are short sold.

Analysts Set New Price Targets

Separately, The Goldman Sachs Group upgraded Sysmex from a “hold” rating to a “buy” rating in a report on Thursday, October 9th. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, Sysmex currently has an average rating of “Moderate Buy”.

Sysmex Trading Down 1.7%

Shares of OTCMKTS:SSMXY opened at $9.34 on Friday. Sysmex has a 52-week low of $9.00 and a 52-week high of $19.85. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.49 and a current ratio of 3.34. The company has a market capitalization of $5.88 billion, a P/E ratio of 18.68 and a beta of 1.13. The company has a 50-day simple moving average of $9.75 and a 200 day simple moving average of $11.89.

Sysmex (OTCMKTS:SSMXY) last released its quarterly earnings data on Wednesday, November 5th. The company reported $0.16 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.16. Sysmex had a return on equity of 9.86% and a net margin of 9.32%.The firm had revenue of $826.60 million for the quarter, compared to analyst estimates of $880.80 million. Sell-side analysts forecast that Sysmex will post 0.57 earnings per share for the current year.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan?based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high?speed, high?volume testing for blood cell counts and differential analysis.